ICP-490 not checked
Beijing InnoCare Pharma Tech Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1/2
- “This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.”In the company’s words, NCT06845241 on ClinicalTrials.gov
Other drugs for Relapsed or Refractory Non-Hodgkin Lymphoma
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up1
- Jul 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | Jul 2028 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | |
| Phase 1/2Unknown | 30 Jul 2025 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026